Rezolute, Inc. (RZLT)
NASDAQ: RZLT · Real-Time Price · USD
4.650
-0.160 (-3.33%)
Jan 23, 2025, 12:20 PM EST - Market open
Rezolute Employees
Rezolute had 59 employees as of June 30, 2024. The number of employees increased by 8 or 15.69% compared to the previous year.
Employees
59
Change (1Y)
8
Growth (1Y)
15.69%
Revenue / Employee
n/a
Profits / Employee
-$1,174,797
Market Cap
269.44M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
RZLT News
- 7 weeks ago - Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Rezolute: Ersodetug Downstream Tech Could Ignite The Hyperinsulinism Market - Seeking Alpha
- 4 months ago - Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - FDA Gives Green Signal To Rezolute's Genetic Disorder Treatment - Benzinga
- 4 months ago - US FDA lifts partial clinical hold on Rezolute's blood sugar treatment - Reuters
- 4 months ago - FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study - GlobeNewsWire
- 6 months ago - Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism - GlobeNewsWire
- 7 months ago - Rezolute Announces Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement - GlobeNewsWire